Biopharmaceutical News and Research

RSS
ATCC announces award from national institute of allergy and infectious diseases to support its preclinical services for biopharmaceutical product development

ATCC announces award from national institute of allergy and infectious diseases to support its preclinical services for biopharmaceutical product development

Data, Design, and Discovery: Andrew Buchanan's Impact on Biologics Innovation

Data, Design, and Discovery: Andrew Buchanan's Impact on Biologics Innovation

MD Anderson and Jazz Pharmaceuticals collaborate to investigate the potential of zanidatamab in HER2-expressing cancers

MD Anderson and Jazz Pharmaceuticals collaborate to investigate the potential of zanidatamab in HER2-expressing cancers

Lario Therapeutics receives “Company Making a Difference Award” from CDLK5 Forum, recognising its unique approach to precision medicine for genetic epilepsies

Lario Therapeutics receives “Company Making a Difference Award” from CDLK5 Forum, recognising its unique approach to precision medicine for genetic epilepsies

UTHSC's drug candidate for advanced prostate cancer goes to first clinical trial

UTHSC's drug candidate for advanced prostate cancer goes to first clinical trial

The New Picus® 2 sets a new standard for connected electronic pipettes

The New Picus® 2 sets a new standard for connected electronic pipettes

Scientists identify nearly a dozen genes responsible for coronary artery calcification

Scientists identify nearly a dozen genes responsible for coronary artery calcification

Study provides evidence for combination therapy as first-line treatment for relapsed ITP

Study provides evidence for combination therapy as first-line treatment for relapsed ITP

Mogrify extends Series A financing to $46 million USD

Mogrify extends Series A financing to $46 million USD

PhenomeX announces the release of SpotLight™ Human Lambda reagent for the Beacon® platform to accelerate cell line development workflows

PhenomeX announces the release of SpotLight™ Human Lambda reagent for the Beacon® platform to accelerate cell line development workflows

Innovations in baculovirus–insect cell expression systems

Innovations in baculovirus–insect cell expression systems

Nuvectis launches Phase 1a dose escalation clinical trial of new cancer drug

Nuvectis launches Phase 1a dose escalation clinical trial of new cancer drug

Organon Bolsters Research & Development Expertise with Two Leadership Appointments

Organon Bolsters Research & Development Expertise with Two Leadership Appointments

Optibrium acquires BioPharmics LLC, expanding its 3D drug design and visualisation offering

Optibrium acquires BioPharmics LLC, expanding its 3D drug design and visualisation offering

Drexel University receives grants to support cell and gene therapy education

Drexel University receives grants to support cell and gene therapy education

Speech Accessibility Project needs more participants with Parkinson's

Speech Accessibility Project needs more participants with Parkinson's

New treatment approach shows promise in reversing hormone resistance in breast cancer

New treatment approach shows promise in reversing hormone resistance in breast cancer

Researchers develop antibody drugs from tobacco plants for cancer treatment

Researchers develop antibody drugs from tobacco plants for cancer treatment

Are mushrooms an effective early dietary intervention for Alzheimer’s Disease?

Are mushrooms an effective early dietary intervention for Alzheimer’s Disease?

GABA-modulating treatments could help tackle cognitive, affective symptoms associated with depression

GABA-modulating treatments could help tackle cognitive, affective symptoms associated with depression

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.